© 2004 BMJ Publishing Group Ltd
EDITORIAL COMMENTARIES
IFN-ß treatment
Is it time to consider rationalising IFN-ß treatment in individuals with multiple sclerosis?
Correspondence to:
Correspondence to:
G Giovannoni
Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK; G.Giovannoni@ion.ucl.ac.uk
Time to rationalise IFN-ß treatment
Keywords: interferon beta; multiple sclerosis; neutralising antibodies; MxA protein
| The first 150 words of the full text of this article appear below. |
In this issue Antonio Bertolotto and colleagues (see pp 1294–9),1 use MxA mRNA expression in peripheral blood mononuclear cells (PBMCs) to assess the in vivo bioactivity of interferon-beta (IFN-ß) treatment in patients with multiple slerosis (MS). MxA transcription and translation is relatively specific for the type 1 interferons, such as interferon-alpha (IFN-
) and IFN-ß, and plays an important role in the anti-viral response. MxA protein can also be used as readout for IFN-ß but with a longer temporal profile.2 MxA is therefore a suitable marker to assess the bioactivity of IFNß—i.e. receptor binding, second messenger activation, gene transcription, and, in the case of MxA protein, gene translation. It appears, however, that quantitative MxA mRNA expression has some advantages over the MxA protein translation. Firstly, it has a wider dynamic range and the RT-qPCR method used to quantify its expression should be easier to standardise.3 Unfortunately,
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
